Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequen...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Cancer J
Autori principali: Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengaß, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, Lokhorst, Henk, Martin, Hans, Goerner, Martin, Hoffmann, Martin, Lindemann, Hans-Walter, Bernhard, Helga, Blau, Igor W., Scheid, Christof, Besemer, Britta, Weisel, Katja C., Hänel, Mathias, Dürig, Jan, Goldschmidt, Hartmut
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7791127/
https://ncbi.nlm.nih.gov/pubmed/33414374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00390-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi